Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442682 | 0.93 | MDM2 (0.72) | MDM2PKMRIPK1KMONOTUM | |
| SCHEMBL1437063 | 0.87 | MDM2 (0.82) | MDM2PKMNOTUMKMT2AKDM4E | |
| SCHEMBL9893965 | 0.85 | MDM2 (0.48) | MDM2RIPK1ALDH1A1 | |
| SCHEMBL27862823 | 0.82 | MDM2 (0.56) | MDM2RIPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9894355 | 0.82 | MDM2 (0.56) | MDM2RIPK1 | |
| SCHEMBL27862830 | 0.81 | MDM2 (0.61) | MDM2RIPK1KMONOTUMKMT2A | |
| SCHEMBL1437150 | 0.81 | MDM2 (0.78) | MDM2PKMNOTUMKDM4EALDH1A1 | |
| SCHEMBL1440068 | 0.80 | MDM2 (0.57) | MDM2ALDH1A1 | |
| SCHEMBL1437138 | 0.80 | MDM2 (0.51) | MDM2PKMRIPK1KMONOTUM | |
| SCHEMBL1437201 | 0.79 | MDM2 (0.53) | MDM2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PKM 2050/4885RIPK1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.